ArticleFrontiers in aging neuroscience2026
Adjunctive EGb 761 treatment in patients with Parkinson's disease: a case series.
Article in Frontiers in aging neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is the second most common neurodegenerative disease. It is based on a gradual decrease in the number of dopaminergic neurons in the midbrain. Since various pathological processes, including oxidative stress, neuroinflammation, and impaired neuroplasticity, are involved in PD pathogenesis, there is increasing interest in adjunctive therapies that target multiple pathways. This study aims to provide a preliminary assessment of the effects of adjunctive EGb 761 on motor, cognitive, and molecular markers in patients with Parkinson's disease, to gain insights valuable for the design of future controlled and randomized clinical trials. Methods: The study included 17 patients with Parkinson's disease who received EGb 761 for 1 month in the context of baseline antiparkinsonian therapy. Standard clinical and neurophysiological tests were performed: UPDRS, MMSE, MoCA, FAB, BDI-I, Spielberger-Hanin Anxiety Scale and Hoehn and Yahr scale, motor tempo and sensorimotor response; the following molecular genetic markers were determined: relative average telomere length, relative mtDNA copy number; and biochemical markers: LDH, SOD and CAT activity, as well as AGEs, GSH/GSSG and MDA concentrations were determined. Results: Statistically significant changes in the relative number of mtDNA copies (decrease), GSH/GSSG (decrease) and MDA (increase), as well as a trend towards telomere elongation were observed. Conclusion: EGb 761 administration in combination with basic symptomatic therapy is associated with improved cognitive and motor functions, and the molecular findings (a decrease in mtDNA copy number alongside a trend toward telomere elongation) are consistent with, though not proof of, the activation of mitophagy. Our preliminary results provide the basis for designing sufficiently powered, randomized and controlled clinical trials with clearly defined primary and secondary endpoints to assess the efficacy and safety of
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.